Literature DB >> 18278192

Male-specific cardiac pathologies in mice lacking either the A or B subunit of factor XIII.

Masayoshi Souri1, Shiori Koseki-Kuno, Naoki Takeda, Mitsunori Yamakawa, Yasuchika Takeishi, Jay L Degen, Akitada Ichinose.   

Abstract

Factor XIII (FXIII) is a proenzyme of plasma transglutaminase consisting of enzymatic A subunits (FXIII-A) and non-catalytic B subunits (FXIII-B), and acts in haemostasis and wound healing. We generated mice lacking either FXIII-A or FXIII-B to investigate the physiological functions of FXIII in vivo. A longitudinal study was carried out using the gene-targeted mice to explore the possible effects of FXIII deficiency on aging. Survival rates of FXIII-A(-/-) males decreased to approximately 50% at 10 months after birth, although most FXIII-A(-/-) females and both genders of wild-type mice survived. Four FXIII-A(-/-) males died of severe intra-thoracic haemorrhage, and a large haematoma was found in their hearts. Haemorrhage, haemosiderin deposition and/or fibrosis were observed in the hearts of other dead FXIII-A(-/-) males. Fibrosis together with haemosiderin deposition was also found in the hearts of FXIII-A(-/-) males sacrificed. The in-vivo cardiac function was normal in FXIII-A(-/-) mice when compared with wild-type mice despite the presence of significant cardiac fibrosis. Although survival rates for both genders of the FXIII-B(-/-) and wild-type mice did not differ, mild fibrosis together with haemosiderin deposits were only found in the hearts of the sacrificed FXIII-B(-/-) males. Carditis and fibrosis in FXIII-deficient mice might be caused by a faulty or delayed reparative process that was initiated by abnormal haemorrhagic events within heart tissue. It is important therefore to examine possible cardiac involvement in human patients with congenital FXIII deficiency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278192     DOI: 10.1160/TH07-10-0599

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  Genetic sequence analysis of inherited bleeding diseases.

Authors:  Flora Peyvandi; Tom Kunicki; David Lillicrap
Journal:  Blood       Date:  2013-10-11       Impact factor: 22.113

2.  Report of a patient with chronic intractable autoimmune hemorrhaphilia due to anti-factor XIII/13 antibodies who died of hemorrhage after sustained clinical remission for 3 years.

Authors:  Takeshi Kotake; Masayoshi Souri; Koji Takada; Satoru Kosugi; Soichi Nakata; Akitada Ichinose
Journal:  Int J Hematol       Date:  2015-02-08       Impact factor: 2.490

Review 3.  Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control.

Authors:  Akitada Ichinose
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

4.  Plasmin-mediated fibrinolysis enables macrophage migration in a murine model of inflammation.

Authors:  Lakmali Munasinghage Silva; Andrew Gary Lum; Collin Tran; Molly W Shaw; Zhen Gao; Matthew J Flick; Niki M Moutsopoulos; Thomas H Bugge; Eric S Mullins
Journal:  Blood       Date:  2019-05-17       Impact factor: 22.113

5.  Reduced difference of α₂-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune hemorrhaphilia due to anti-factor XIII antibodies.

Authors:  Akitada Ichinose; Masayoshi Souri
Journal:  Int J Hematol       Date:  2011-12-29       Impact factor: 2.490

Review 6.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

7.  The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits.

Authors:  James R Byrnes; Clare Wilson; Anthony M Boutelle; Chase B Brandner; Matthew J Flick; Helen Philippou; Alisa S Wolberg
Journal:  Blood       Date:  2016-08-25       Impact factor: 22.113

8.  Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain.

Authors:  Eric S Mullins; Keith W Kombrinck; Kathryn E Talmage; Maureen A Shaw; David P Witte; Joni M Ullman; Sandra J Degen; William Sun; Matthew J Flick; Jay L Degen
Journal:  Blood       Date:  2008-10-16       Impact factor: 22.113

9.  Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice.

Authors:  Maureen A Shaw; Keith W Kombrinck; Kathryn E McElhinney; David R Sweet; Matthew J Flick; Joseph S Palumbo; Mei Cheng; Naomi L Esmon; Charles T Esmon; Alexander Brill; Denisa D Wagner; Jay L Degen; Eric S Mullins
Journal:  Blood       Date:  2016-06-01       Impact factor: 22.113

10.  Application of Dynamic Contrast Enhanced Magnetic Resonance Imaging to Evaluate Angiogenic Response and Vascular Permeability.

Authors:  Mary C Wallingford; Tomo Tarui; Nirmala Jayaraman; Gordon S Huggins; Manjiri K Dighe
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-24       Impact factor: 10.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.